COMMUNIQUÉS West-GlobeNewswire

Glasses go 'bio'. Partnership between Bio-on and Kering Eyewear.
05/09/2017
The two companies will work together on new eco-sustainable materials to match and exceed the characteristics of the plastics used to date in eyewear The aim is to create a series of innovative materials to broaden [...]
Les lunettes deviennent «bio». Avènement d'un partenariat entre Bio-on et Kering Eyewear.
05/09/2017
Les deux entreprises étudieront ensemble de nouveaux matériaux éco-durables, dont les caractéristiques sont comparables, voire supérieures, à celles des matières plastiques utilisées jusqu'à présent dans le secteur de [...]
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
05/09/2017
Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a There is a significant unmet need for safe and effective MS [...]
TiGenix obtains commercial production license for expanded manufacturing facility
05/09/2017
PRESS RELEASE TiGenix obtains commercial production license for expanded manufacturing facility - Provides capacity for potential European commercial roll out of investigational stem cell therapy, Cx601 - Expanded [...]
TiGenix obtient la licence de production commerciale pour son centre de fabrication élargi
05/09/2017
COMMUNIQUÉ DE PRESSE TiGenix obtient la licence de production commerciale pour son centre de fabrication élargi - Le centre a une capacité suffisante pour la commercialisation éventuelle en Europe du Cx601, une thérapie [...]
Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA
05/09/2017
PRESS RELEASE: 5 September 2017, 07:00 CEST Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA First test cleared for use on the Idylla(TM) platform by US FDA Mechelen, Belgium, 5 September 2017 [...]
Santhera Announces Financial Results for the First Half-Year 2017 and Reports Commercial and Development Progress
05/09/2017
Liestal, Switzerland, September 5, 2017 - Santhera Pharmaceuticals (SIX: SANN) reports first half-year results as of June 30, 2017: 1H 2017 sales of CHF 10.9 million, increase of 51% compared to 1H 2016 Successful [...]
Les données publiées dans The Lancet montrent des résultats positifs au niveau du terminal primaire dans le traitement de l'hypertension résistante avec le dispositif MobiusHD
05/09/2017
Cette publication fait suite aux résultats intermédiaires positifs chez les patients des États-Unis et de l'UE présentés lors de la conférence de la Société européenne de cardiologie MOUNTAIN VIEW, Californie, le 1 er [...]
Sanofi: Disclosure of trading in own shares
04/09/2017
Disclosure of trading in own shares This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]
Sanofi : Déclaration des transactions sur actions propres
04/09/2017
Déclaration des transactions sur actions propres This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are [...]
NICOX : Nombre de droits de vote au 31 août 2017
04/09/2017
Nicox SA Société anonyme au capital de 29 169 338 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 4 septembre 2017, PUBLICATION MENSUELLE DU NOMBRE D' [...]
NICOX : Number of voting rights as of August 31. 2017
04/09/2017
Nicox SA Société anonyme with a registered capital of € 29,169,338 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On September 4, 2017, MONTHLY PUBLICATION OF THE [...]
Ossur Hf : Transactions in relation to share buyback program
04/09/2017
Announcement from Össur hf. No. 65/2017 Reykjavík, 4 September 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Novo Nordisk A/S: Share repurchase programme
04/09/2017
Bagsværd, Denmark, 4 September 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Faron Pharmaceuticals Oy: Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine® following completion of European and Japanese Phase III studies
04/09/2017
Faron Pharmaceuticals Ltd ("Faron" or the "Company") Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine ® following completion of European and Japanese Phase III studies TURKU - [...]
Midatech Pharma Plc: Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly
04/09/2017
4 September 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly Midatech on track to start clinical development with [...]
Solon Eiendom ASA - Primary insider notification
04/09/2017
SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 4 September 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company [...]
Affimed to Present at the 2017 Wells Fargo Healthcare Conference - Boston
04/09/2017
Heidelberg, Germany, September 4, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi [...]
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
04/09/2017
Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position. The Board of Directors [...]

Pages